LUNG CANCER

In a Targeted Oncology Case-Based Roundtable event Edward S. Kim, MD, MBA, discussed new regimens for the treatment of non-small cell lung cancer.

The FDA has accepted the supplemental biologics license application submitted for atezolizumab as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer whose tumors express PD-L1≥1%, as determined by an FDA-approved test and granted it priority review.

In an interview with Targeted Oncology™, Robert Coleman, MD, discussed the evolving treatment paradigm of lung cancer and the role of molecular testing now and in the future. 

In an interview with Targeted Oncology, Jorge A. Rios, MD, discusses recent advances in non–small cell lung cancer and the role targeted and immune checkpoint inhibitor therapy has played in this progress.

During a Targeted Oncology Case-Based Roundtable event, Jarushka Naidoo, MB, BCh, MHS. discussed the case of a 73-year-old patient with small cell lung cancer who first presented with shortness of breath, productive cough, chest pain, and fatigue.

Edward S. Kim, MD, MBA discusses immunotherapy-realted adverese events in non-small cell lung cancer in a rountable discussion with Albert Dekker, MD and Sam Yeh, MD.

Edward B. Garon, MD, MS leads a roundtable discussion on the impact of RET mutations on the lung cancer space.

During a Targeted Oncology Case-Based Roundtable event, Grace K. Dy, MD and 9 other physicians discussed molecular testing for patients with non–small cell lung cancer.

The FDA has granted an orphan drug designation to the anticancer drug paclitaxel-hyaluronic acid for the treatment of malignant mesothelioma.

According to a poll, the majority of physicians would wait for molecular testing on a patient metastatic lung adenocarcinoma. Then, upon diagnosis of RET-mutant non–small cell lung cancer, a group of oncologists explained how they would go about treatment for the patient.

Ronald J. Scheff, MD, reviews the molecular testing practices for non–small cell lung cancer and frontline treatment of patients with PD-L1-positive non–small cell lung cancer during a Case-Based Roundtable event.

Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival versus supportive care in patients with PD-L1–positive non–small cell lung cancer.

Eric Nadler, MD, MPP, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment studied in the IMpower133 trial in extensive-stage small cell lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Balazs Halmos, MD, MS, discussed the case of a 73-year-old patient with early-stage small cell lung cancer.

In 2017, the American Society of Clinical Oncology and the Ontario Health-Cancer Care Ontario's non–small cell lung cancer expert panel published a guideline with recommendations for systemic therapy for patients with stage IV NSCLC.

Targeted Therapies in Oncology spoke with Martin J. Edelman, MD, do uncover what is next for small cell lung cancer after PD-1 inhibitor indication have been withdrawn.

Eric Nadler, MD, MPP, lead a Cased-Based Roundtable event during which participants discussed how PD-L1 expression in patient with non–small cell lung cancer impacts treatment decisions.

During a Targeted Oncology Case-Based Roundtable event, Catherine Shu, MD, moderated a discussion around the case of a 77-year-old patients with non–small cell lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Jessica Bauman, MD, discussed the case of 59-year-old patient with RET-mutated non–small cell lung cancer.

Ticiana Leal, MD, explained her approach to treating a patient with extensive-stage small cell lung cancer, during a Targeted Oncology Case-Based Roundtable event.

Jyoti Malhotra, MD, MPH, discusses the preliminary efficacy signals of the combination therapy plinabulin, nivolumab, and ipilimumab in patients with relapsed/refractory small cell lung cancer.

Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

The investigational next-generation tyrosine kinase inhibitor, taletrectinib has been dosed for the first time in a patient with an NTRK fusion-positive solid tumor being treated in a phase 2 study.

A frontline regimen nivolumab, ipilimumab, and 2 cycles of chemotherapy yielded an improvement in overall survival versus chemotherapy alone in patients with advanced non–small cell lung cancer. The benefit was observed regardless of tumor mutational burden status in the tissue or blood.

In an interview with Targeted Oncology, Aaron Lisberg, MD spoke on the importance of molecular testing for patients with lung adenocarcinoma, and provided tips for choosing between immunotherapy and a tyrosine kinase inhibitor.

Hossein Borghaei, DO, shares insights regarding future directions and current unmet needs in extensive-stage small cell lung cancer. He provides advice to researchers about the importance of clinical trials in the setting of extensive-stage small cell lung cancer.

An expert oncologist, Hossein Borghaei, DO considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed/refractory small-cell lung cancer.

A thought leader in lung cancer, Hossein Borghaei, DO, reviews safety and efficacy data from the phase 2 basket trial of lurbinectedin in selected advanced solid tumors.

Hossein Borghaei, DO, reviews the second-line treatment options in the setting of extensive-stage small cell lung cancer: topotecan or lurbinectedin.

Hossein Borghaei, DO, reviews the currently accepted first-line treatment recommendation for extensive-stage small cell lung cancer: a triple combination of carboplatin, etoposide, and a checkpoint inhibitor (atezolizumab or durvalumab). He provides an overview of the IMpower and CASPIAN trials.